Trials / Active Not Recruiting
Active Not RecruitingNCT05665699
Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
A Randomized, Open-Label, Multiple-Dose Phase II Study to Evaluate Efficacy and Safety of D-0120 Administered in Combination With Allopurinol in Subjects With Gout
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- InventisBio Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
D-0120 is being tested in combination with Allopurinol in adult subjects with Gout.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | D-0120 | increasing dose of D-0120 |
| DRUG | Allopurinol | standard dosing |
Timeline
- Start date
- 2023-04-17
- Primary completion
- 2025-07-31
- Completion
- 2025-12-30
- First posted
- 2022-12-27
- Last updated
- 2025-05-08
Locations
19 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05665699. Inclusion in this directory is not an endorsement.